• +1-646-491-9876
    • +91-20-67278686

    Search

    Vulvar Cancer-Pipeline Review H1 2017

    Vulvar Cancer-Pipeline Review H1 2017

    • Report Code ID: RW0001834370
    • Category Pharmaceuticals
    • No. of Pages 76
    • Publication Month Jun-17
    • Publisher Name Global Markets Direct
    Vulvar Cancer - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Vulvar Cancer - Pipeline Review, H1 2017, provides an overview of the Vulvar Cancer (Oncology) pipeline landscape.

    Vulvar cancer is a rare type of cancer. It forms in a woman's external genitals, called the vulva. The cancer usually develops slowly over several years. First, precancerous cells grow on vulvar skin. This is called vulvar intraepithelial neoplasia (VIN) , or dysplasia. Not all VIN cases turn into cancer, but it is best to treat it early.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Vulvar Cancer - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Vulvar Cancer (Oncology) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Vulvar Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vulvar Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II stages are 5 respectively.

    Vulvar Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Vulvar Cancer (Oncology) .
    - The pipeline guide reviews pipeline therapeutics for Vulvar Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Vulvar Cancer (Oncology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Vulvar Cancer (Oncology) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Vulvar Cancer (Oncology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Vulvar Cancer (Oncology) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Vulvar Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Vulvar Cancer - Overview
    Vulvar Cancer - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Vulvar Cancer - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Vulvar Cancer - Companies Involved in Therapeutics Development
    Cutanea Life Sciences Inc
    ISA Pharmaceuticals BV
    Oryx GmbH & Co KG
    PDS Biotechnology Corp
    Vulvar Cancer - Drug Profiles
    ISA-101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    nivolumab - Drug Profile
    R&D Progress
    omiganan pentahydrochloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PDS-0101 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vicoryx - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Vulvar Cancer - Dormant Projects
    Vulvar Cancer - Product Development Milestones
    Featured News & Press Releases
    Oct 05, 2011: FDA Grants ISA Pharmaceuticals Orphan Drug Designation For Treatment Of Vulvar Intraepithelial Neoplasia With ISA-HPV-SLP
    Mar 07, 2011: ISA Pharma Receives €2.7m From Dutch Government To Further Clinical Development Of HPV-SLP Vaccine
    Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials
    Jun 02, 2010: Bachem To Supply ISA Pharmaceuticals With Finished Dosage Forms Immunotherapeutic HPV-SLP For Phase III Clinical Trials
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Vulvar Cancer, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Vulvar Cancer - Pipeline by Cutanea Life Sciences Inc, H1 2017
    Vulvar Cancer - Pipeline by ISA Pharmaceuticals BV, H1 2017
    Vulvar Cancer - Pipeline by Oryx GmbH & Co KG, H1 2017
    Vulvar Cancer - Pipeline by PDS Biotechnology Corp, H1 2017
    Vulvar Cancer - Dormant Projects, H1 2017

    List of Figures

    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Cutanea Life Sciences Inc
    ISA Pharmaceuticals BV
    Oryx GmbH & Co KG
    PDS Biotechnology Corp

    Request for Sample

    Report Url https://www.reportsweb.com//vulvar-cancer-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//vulvar-cancer-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//vulvar-cancer-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments